2018 American Transplant Congress
A Comparison of Alemtuzumab versus Antithymocyte Globulin Induction in High-Risk, Non-Sensitized Renal Transplant Recipients
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Lymphocyte depleting induction is routinely utilized in high immunologic risk renal transplant (RTx). African Americans (AA) have a relatively higher risk of rejection regardless…2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Heart/Kidney Transplantation
Virginia Commonwealth University, Richmond.
Introduction: There is no published data on the risks and benefits of Induction immunosuppression in simultaneous heart/kidney transplant (SHKT) patients.Methods: We analyzed all SHKT performed…2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…2018 American Transplant Congress
The Influence of Rabbit Antithymocyte Globulin (rATG) Dose on the Incidence of CMV Infection in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis. A Propensity Score Matched Cohort Analysis
rATG has become the agent of choice for induction therapy in sensitized patients and those receiving expanded criteria donors (ECD) allografts. However, the optimal dose…2018 American Transplant Congress
T-Cell Depletion Does Not Increase the Risk of CMV Infection in Donor-Positive, Recipient-Negative Kidney Transplants Due to the Absence of Preformed CMV-Specific Cell-Mediated Immunity
Kidney transplants (KT) with R-/D+ CMV serostatus receiving T-cell depletion induction are considered as the highest risk population for CMV infection and long-lasting prophylaxis therapy…2018 American Transplant Congress
Cost Impacts of Alternative Kidney Transplant Immunosuppression: A National Cohort Study
Economic outcomes are increasingly considered along with clinical efficacy to guide choice of alternative therapies. We examined the cost impact of kidney transplant (KTx) induction…2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…2018 American Transplant Congress
Ideal Body Weight versus Actual Body Weight for Rabbit Antithymocyte Globulin Induction in Pancreas Transplantation
Purpose: Rabbit antithymocyte globulin (rATG) is the most commonly used induction agent in solid organ pancreas transplantation. The optimal induction dosing of rATG, has not…2018 American Transplant Congress
Alemtuzumab Induction is Effective and Safe in Elderly Kidney Transplant Recipients
University of North Carolina, Chapel Hill.
Purpose of this study is to determine safety of Alemtuzumab (Ab) in elderly kidney recipients.MethodsThis is a retrospective single center cohort analysis concerning kidney transplant…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 31
- Next Page »